CTAS vs EDIT · P/E 51, rev $10.34B vs rev $32.3M
Cintas Corporation (CTAS) versus Editas Medicine Inc (EDIT) — a side-by-side from cached financials, not a winner call.
Cintas Corporation (CTAS) is a specialty business services company listed on US.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
Latest reported CTAS revenue for 2025-05-31 was $10.34B. Net income was $1.81B. Revenue was up 7.7% from 2024-05-31 to 2025-05-31. CTAS currently screens at market cap $89.01B and trailing P/E 51.3.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
CTAS currently screens at market cap $89.01B and trailing P/E 51.3. EDIT currently screens at market cap $375.2M.
Not investment advice. Open the CTAS and EDIT stock pages for the full models.
Not investment advice.